New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the…
Multiplier Unveils Major Shifts in Global Hiring: US-to-Canada Hiring Expands by 170%, International Hiring for Leadership Roles Rises, and Commercial Roles Outpace Tech
Based on data from over 38,000 cross-border hires, Multiplier’s Talent Trends reveals…